The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs - Those who took the pill lost around 13 per cent of their body weight over three months ...

Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in ...

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...